Merck's mRNA Melanoma Vaccine Cuts Recurrence in Late-Stage Trial
MRK sits 97% above its 52-week low of $77.58.
Summary
Merck's personalized mRNA melanoma vaccine, combined with Keytruda, significantly reduced recurrence versus Keytruda alone in a late-stage trial. This is a major advance in oncology and could expand Merck's immuno-oncology franchise. Separately, proposed vaccine policy shifts may affect M-M-R II and ProQuad, adding regulatory uncertainty. The stock is trading near its 52-week high, reflecting strong pipeline momentum.
At the time of this announcement, MRK was trading at $153.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $376.4B. The 52-week trading range was $77.58 to $154.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.